Methylenetetrahydrofolate Reductase and Thymidylate Synthase Genotypes and Risk of Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia
Open Access
- 1 September 2006
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 12 (9) , 973-980
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexateBone Marrow Transplantation, 2006
- Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantationBone Marrow Transplantation, 2006
- Pharmacogenetics of folate-related drug targets in cancer treatmentPharmacogenomics, 2005
- Graft-vs-host disease after non-myeloablative hematopoietic cell transplantationLeukemia & Lymphoma, 2005
- Pharmacogenetics of outcome in children with acute lymphoblastic leukemiaBlood, 2005
- Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous LeukemiaClinical Cancer Research, 2004
- Predictors of Oral Mucositis in Patients Receiving Hematopoietic Cell Transplants for Chronic Myelogenous LeukemiaJournal of Clinical Oncology, 2004
- Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid LeukemiaNew England Journal of Medicine, 1998
- A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductaseNature Genetics, 1995
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986